EQL Pharma AB (EQL)

Currency in SEK
26.0500
-0.4500(-1.70%)
Closed·

EQL Earnings

Latest Release
Aug 07, 2026
EPS / Forecast
0.11 / 0.25
Revenue / Forecast
107M / 114M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/0.120--/114.70M----Free Sign Up
2026/060.110/0.250107.00M/114.00M-56%-6.14%Free Sign Up
2026/030.320/0.300120.10M/123.80M+6.67%-2.99%Free Sign Up
2025/120.330/0.200118.95M/114.85M+65%+3.57%Free Sign Up
2025/09-0.110/0.45086.20M/115.35M-124.44%-25.27%Free Sign Up
2025/060.340/--107.10M/114.20M---6.22%Free Sign Up
2025/030.440/0.450113.26M/102.75M-2.22%+10.23%Free Sign Up
2024/120.350/0.46092.00M/94.75M-23.91%-2.9%Free Sign Up
2024/090.330/0.22085.10M/85.00M+50%+0.12%Free Sign Up
2024/060.360/0.28082.90M/82.90M+28.57%0%Free Sign Up

All numbers in SEK

EQL Pharma AB Earnings Call Summary for Q1/2027

  • Q1 sales flat YoY; gross margin fell to 17% from 43% due to SEK 20M inventory write-down and supply issues.
  • Operating expenses surged 23% YoY to SEK 31.5M; stock-outs improved from 5-7 products to 1-2 entering Q2.
  • Company maintains 15% full-year sales growth target despite weak Q1; expects Q2-Q3 recovery as inventory normalizes.
  • Seven product launches planned for 2025; Memprex API switch approval targeted early 2026 to boost margins mid-year.
  • CEO calls Q1 'low water mark'; no covenant breach expected but elevated leverage monitored closely amid recovery efforts.
Last Updated: 2026-08-07, 05:18 a/m
Read Full Transcript

FAQ

What Is EQL Pharma's Earnings Per Share (TTM)?

The EQL Pharma EPS (TTM) is -0.4737.

When Is The Next EQL Pharma Earnings Date?

EQL Pharma will release its next earnings report on Nov 05, 2026.

What Is EQL Pharma’s Revenue Forecasts For Upcoming Quarters?

EQL Pharma’s revenue forecast is 114.70M.

How Did EQL Pharma React to the Company's Latest Earnings Report?

EQL Pharma reported a -56% EPS surprise and a -6.14% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -5.3000%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.